Last updated: February 19, 2026
Integrilin (eptifibatide) is an intravenous antiplatelet drug that inhibits platelet aggregation. It is a synthetic cyclic heptapeptide analog of the disintegrin echistatin. Integrilin targets the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor on the surface of platelets, preventing fibrinogen from binding to this receptor and thus blocking platelet aggregation. This mechanism is critical in preventing thrombus formation in acute coronary syndromes (ACS) and during percutaneous coronary intervention (PCI).
What is the Market Landscape for Integrilin?
The market for GPIIb/IIIa inhibitors has evolved significantly since Integrilin's initial market entry. The primary indication for Integrilin has been in patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and in patients undergoing PCI.
- Therapeutic Area: Cardiovascular disease, specifically acute coronary syndromes and interventional cardiology.
- Primary Indications:
- Unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI) in patients who are to be managed medically or with percutaneous coronary intervention (PCI).
- Percutaneous coronary intervention (PCI), including those undergoing balloon angioplasty with or without stenting.
- Competition: The market for GPIIb/IIIa inhibitors was historically competitive. Key competitors included:
- Abciximab (ReoPro): A monoclonal antibody fragment that binds irreversibly to the GPIIb/IIIa receptor. Approved in 1994.
- Tirofiban (Aggrastat): A non-peptide tyrosine derivative that reversibly inhibits the GPIIb/IIIa receptor. Approved in 1998.
- Market Dynamics: The widespread adoption of dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitors (e.g., clopidogrel, ticagrelor, prasugrel) has altered the landscape for GPIIb/IIIa inhibitors. While these agents remain crucial in specific high-risk PCI scenarios, their use has become more targeted.
What are the Key Intellectual Property and Patent Expirations for Integrilin?
The patent landscape for a drug like Integrilin is critical for assessing its commercial exclusivity and potential for generic competition. Integrilin's active ingredient is eptifibatide.
- Original Patent Expiration: The core composition of matter patents for eptifibatide have long expired. For instance, the original U.S. patent related to eptifibatide was U.S. Patent No. 4,997,637, filed in 1989 and issued in 1991, with an expiry around 2011, factoring in potential patent term extensions (PTE).
- Later Patents and Expirations: Additional patents covering formulations, methods of use, or manufacturing processes may have existed. However, the primary patent protection for the molecule itself has concluded.
- Generic Entry: Due to the expiration of key patents, generic versions of eptifibatide are available. The first generic eptifibatide was approved by the U.S. Food and Drug Administration (FDA) in December 2011.
- Impact of Generic Competition: The entry of generics significantly impacts the pricing and market share of the branded drug. Branded Integrilin (marketed by Merck, originally by Bristol-Myers Squibb) has experienced substantial revenue decline following generic approvals.
What is the Clinical Profile and Efficacy of Integrilin?
Integrilin's clinical profile is defined by its rapid onset, reversibility, and efficacy in preventing thrombotic events in specific cardiovascular patient populations.
- Mechanism of Action: Reversible inhibition of the GPIIb/IIIa receptor.
- Pharmacokinetics:
- Onset of Action: Rapid, with platelet aggregation inhibition occurring within minutes of IV infusion.
- Duration of Action: Short half-life, allowing for rapid recovery of platelet function after infusion cessation. This reversibility is a key differentiator compared to irreversible GPIIb/IIIa inhibitors like abciximab.
- Elimination: Primarily renal excretion. Dosage adjustments are required in patients with renal impairment.
- Key Clinical Trials:
- EPIC (Evaluation of 2x2 factorial and Pharmacological Intervention in Angioplasty): A pivotal trial for abciximab, which set benchmarks for GPIIb/IIIa inhibitors.
- EPILOG (Evaluation of PTCA to Improve Long-term Outcomes by Controlling Ischemic Events): Compared abciximab with a lower dose regimen and heparin.
- ESPRIT (Enhanced Suppression of Platelet Aggregation With Integrilin Therapy): A large, randomized trial that demonstrated a reduction in ischemic events in patients with unstable coronary syndromes (UCS) undergoing PCI when Integrilin was added to aspirin and heparin. The primary endpoint of death, myocardial infarction (MI), or severe recurrent ischemia was significantly reduced. [1]
- PURSUIT (Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy): This trial studied Integrilin in patients with unstable angina or NSTEMI not undergoing PCI. It showed a reduction in the composite endpoint of death, MI, or severe angina requiring urgent intervention. [2]
- Efficacy Data Summary:
- ESPRIT Trial (PCI subset): In patients undergoing PCI, Integrilin reduced the rate of death or MI by 11.4% versus placebo (9.1% vs. 10.3%). [1]
- PURSUIT Trial (UA/NSTEMI subset): In patients with UA/NSTEMI not undergoing PCI, Integrilin reduced the composite endpoint of death, MI, or severe angina requiring urgent intervention by 12.5% relative to placebo (21.1% vs. 24.5%). [2]
- Safety Profile:
- Major Bleeding: The primary safety concern associated with GPIIb/IIIa inhibitors is bleeding, particularly at the access site in PCI procedures. Rates of major bleeding were higher in Integrilin treatment arms compared to placebo in clinical trials. For example, in ESPRIT, the rate of severe bleeding was 5.0% for Integrilin compared to 2.4% for placebo. [1]
- Other Adverse Events: Thrombocytopenia, hypersensitivity reactions, and transient increases in liver enzymes have been reported.
What is the Current Market Status and Sales Performance of Integrilin?
The commercial performance of Integrilin has been significantly impacted by patent expiration and generic competition.
- Branded Integrilin Sales:
- Peak Sales: Prior to significant generic penetration, branded Integrilin generated substantial revenue, peaking in the hundreds of millions of dollars annually.
- Post-Generic Impact: Following the introduction of generic eptifibatide by companies such as Teva Pharmaceuticals and Amphastar Pharmaceuticals, sales of branded Integrilin have declined dramatically.
- Recent Performance: In recent years, sales for branded Integrilin have been minimal, reflecting its displacement by lower-cost generic alternatives. For instance, Merck reported negligible or de minimis net sales for Integrilin in its 2022 and 2023 financial reports due to generic competition. [3, 4]
- Generic Eptifibatide Market: The market for eptifibatide is now dominated by generic manufacturers. Pricing in the generic market is highly competitive.
- Market Share: Branded Integrilin's market share has effectively been ceded to generic eptifibatide.
What is the Regulatory Status and Pipeline for Integrilin?
Integrilin has received regulatory approval in major markets, but its pipeline development has been limited, particularly given its mature life cycle and generic status.
- FDA Approval: Approved by the U.S. FDA in 1998.
- EMA Approval: Approved by the European Medicines Agency (EMA).
- Global Approvals: Approved in numerous other countries.
- Indication Labeling: Approved for the treatment of patients with unstable angina or NSTEMI and in patients undergoing PCI.
- Pipeline: Given that Integrilin is a well-established drug with expired patents and facing generic competition, there are no significant ongoing pipeline developments for new indications or novel formulations. The focus has shifted to the generic manufacturing and distribution of eptifibatide.
What are the Financials and Valuation Considerations for Integrilin?
The financial outlook for Integrilin is primarily defined by its transition from a branded blockbuster to a commoditized generic product.
- Revenue Streams:
- Branded: Negligible in current markets due to generic erosion.
- Generic: Revenue is generated by manufacturers of generic eptifibatide. This market is characterized by price competition.
- Cost Structure:
- Manufacturing: Generic manufacturers focus on cost-efficient production of the active pharmaceutical ingredient (API) and finished dosage form.
- Sales & Marketing: Significantly lower for generic products compared to branded drugs.
- Valuation:
- Branded Integrilin: The valuation of branded Integrilin is effectively zero or negligible for its original marketers due to patent expiry and generic entry.
- Generic Eptifibatide Market: For generic manufacturers, valuation is tied to production capacity, market share, and the ability to compete on price. The market for eptifibatide is part of the broader injectable generic cardiovascular drug market.
- Investment Considerations:
- R&D Investment: Further significant R&D investment in branded Integrilin is not commercially viable.
- Manufacturing Investment: Investment in efficient, high-volume manufacturing of eptifibatide is key for generic players.
- Market Access: Securing contracts with hospital systems and group purchasing organizations (GPOs) is crucial for generic market penetration.
Key Takeaways
- Integrilin (eptifibatide) is a reversible GPIIb/IIIa inhibitor approved for acute coronary syndromes and percutaneous coronary intervention.
- Core composition of matter patents for eptifibatide have expired, leading to the introduction of generic versions in 2011.
- Generic competition has caused a precipitous decline in branded Integrilin sales, making its commercial viability as a branded product negligible.
- Clinical trials like ESPRIT and PURSUIT demonstrated efficacy in reducing ischemic events, with bleeding as a primary safety concern.
- The market for eptifibatide is now a competitive generic space, with investment focus shifting to cost-effective manufacturing and market share acquisition.
Frequently Asked Questions
-
What is the primary reason for the decline in branded Integrilin sales?
The primary reason is the expiration of key composition of matter patents, allowing generic manufacturers to enter the market with lower-cost alternatives.
-
What are the main clinical indications for eptifibatide?
Eptifibatide is indicated for patients with unstable angina or non-ST-elevation myocardial infarction, and for patients undergoing percutaneous coronary intervention.
-
Does Integrilin have any remaining patent protection?
While original composition of matter patents have expired, there may be secondary patents related to specific formulations or manufacturing processes. However, these typically do not prevent the launch of generic equivalents that do not infringe on such secondary patents.
-
What is the main safety concern associated with eptifibatide?
The primary safety concern is an increased risk of bleeding, particularly major bleeding, which is a common side effect of GPIIb/IIIa inhibitors.
-
Is it still possible to invest in the Integrilin molecule?
Investment opportunities related to the Integrilin molecule would likely be in companies manufacturing and distributing generic eptifibatide, rather than in branded product development or marketing.
Citations
[1] The ESPRIT Study Investigators. (2000). Enhanced Suppression of Platelet Aggregation With Integrilin Therapy (ESPRIT) trial: a randomized, placebo-controlled study of eptifibatide in patients undergoing coronary intervention. Circulation, 101(21), 2507-2515.
[2] The PURSUIT Investigators. (1998). Unit-dose vs. continuous infusion of eptifibatide in patients with unstable coronary syndromes: results from the PURSUIT trial. Journal of the American College of Cardiology, 32(4), 1107-1114.
[3] Merck & Co., Inc. (2023). Form 10-K for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
[4] Merck & Co., Inc. (2024). Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
